^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR exon 21 mutation + TP53 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P89.15 - Multiple Driver Oncogenes from Plasma of NSCLC Patients
Published date:
01/12/2021
Excerpt:
A second case was a 52 year old female with diagnosis of lung adenocarcinoma T4N3M1 EGFR mutation exon 19, and was treated with erlotinib. She was PD, and the result was EGFR mutation del 19, exon 21, and TP53.
